Attached files
| file | filename |
|---|---|
| EX-99.1 - RADIENT PHARMACEUTICALS Corp | v218937_ex99-1.htm |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 ACT REPORTING REQUIREMENTS
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
Date of Report (Date of Earliest Event Reported): April 18, 2011
Radient Pharmaceuticals Corporation
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-16695
|
33-0413161
|
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(IRS Employer Identification
No.)
|
2492 Walnut Avenue, Suite 100, Tustin, California, 92780-7039
(Address of principal executive offices (zip code))
714-505-4461
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))
Section 2 – Financial Information
Item 2.02: Results of Operations and Financial Condition
Section 7 – Regulation FD
Item 7.01 – Regulation FD Disclosure
Section 8 – Other Events
Item 8.01: Other Events
As disclosed in the Current Report on Form 8-K that we filed with the Securities and Exchange Commission on April 14, 2011 (the “April 14th Form 8-K”), we had our appeals hearing before the NYSE Amex (the “Exchange”) Listing Qualifications Panel (the “Panel”), on April 14, 2011, during which our inability to file our Form 10-K for fiscal 2010 (the “Form 10-K”) by the required April 15, 2011 date, as also disclosed in the April 14th Form 8-K, was discussed. As a result, the Exchange requested that we issue a press release regarding the late filing and include certain preliminary financial data.
Accordingly, on April 18, 2011 we issued a press release disclosing the requested information and such press release is attached as Exhibit 99.1 hereto.
With regards to our appeals hearing, we have not yet received the Panel’s determination, but will promptly provide an update to the public following receipt of same.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
|
Exhibit No.
|
Description
|
|
|
99.1
|
|
Press Release
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
RADIENT
PHARMACEUTICALS
CORPORATION
|
||
|
/s/ Akio Aruira
|
||
|
Name: Akio Aruira
|
||
|
Title: Chief Financial Officer
|
||
Dated: April 18, 2011